TxCell rounds up $16M in second round

France's TxCell has booked up €10.5 million (about $16 million) in a second round of venture funding. Previous investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure all participated. TxCell, which develops therapies for autoimmune and chronic inflammatory diseases, will use the funding to progress its development programs on Crohn's disease, rheumatoid arthritis and a number of orphan diseases.

"This fundraising testifies to the confidence that TxCell's longstanding investors have placed in our company and confirms the great potential of this cell therapy approach (based on the biological properties of Tr1 regulatory lymphocytes) for the treatment of autoimmune and chronic inflammatory diseases", commented Frédéric Hammel, CEO of TxCell.

- read this release

Suggested Articles

Peter Doshi has penned an opinion piece in the BMJ pointing out that current COVID-19 vaccine tests are not set up to save lives.

You may have heard of T cells before, but Aleks Radovic-Moreno, Be Biopharma’s co-founder, is betting on B cells as the future of cell therapies.

Doctors may prescribe steroids or eye drops for patients with dry eye disease. But Azura Ophthalmics wants to do one better.